ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

PR Firm Hired By American Cancer Society Also Represents “Team KOOL Green”.

January 28, 2000

Congress Mandates NIH Cut PR Costs, Coordinate Spending on Communications

January 31, 2014

CDC Contribution To National Dialogue Raises Questions About Ties With ACS.

September 22, 2000

Corrections Made To NCI Phone Directory

May 17, 1991

FDA Opponents Claim Abuses; Agency Doesn’t Attend Hearing

July 28, 1995

NIH Workshop On Animal Care Planned

May 4, 1990